scispace - formally typeset
N

Nesli-Ece Sen

Researcher at Goethe University Frankfurt

Publications -  25
Citations -  460

Nesli-Ece Sen is an academic researcher from Goethe University Frankfurt. The author has contributed to research in topics: Spinocerebellar ataxia & Ataxin. The author has an hindex of 10, co-authored 22 publications receiving 344 citations. Previous affiliations of Nesli-Ece Sen include Boğaziçi University.

Papers
More filters
Journal ArticleDOI

Ataxin-2 (Atxn2)-Knock-Out Mice Show Branched Chain Amino Acids and Fatty Acids Pathway Alterations

TL;DR: Overall, ATXN2 appears to modulate nutrition and metabolism, and its activity changes are determinants of growth excess or cell atrophy, in good agreement with recent claims that PBP1, the yeast ortholog of ATXn2, sequestrates the nutrient sensor TORC1 in periods of cell stress.
Journal ArticleDOI

Efficient Prevention of Neurodegenerative Diseases by Depletion of Starvation Response Factor Ataxin-2

TL;DR: In this paper, it was shown that ATXN2 depletion is surprisingly efficient in preventing motor neuron and cerebellar atrophy, as demonstrated in mouse models, flies, and yeast.
Journal ArticleDOI

Search for SCA2 blood RNA biomarkers highlights Ataxin-2 as strong modifier of the mitochondrial factor PINK1 levels.

TL;DR: Findings suggest that ATXN2 may modify the known PINK1 roles for mitochondrial quality control and autophagy during cell stress, which provides a concept how the degeneration of nigrostriatal dopaminergic neurons and the Parkinson phenotype may be triggered by ATXn2 mutations.
Journal ArticleDOI

Generation of an Atxn2-CAG100 knock-in mouse reveals N-acetylaspartate production deficit due to early Nat8l dysregulation.

TL;DR: A novel authentic rodent model of SCA2 is presented, where in vivo magnetic resonance imaging was feasible to monitor progression and where the definition of earliest transcriptional abnormalities was possible, and it is believed that this model will reveal crucial insights regarding the pathomechanism ofSCA2 and other ATXN2-associated disorders, but will also aid in developing gene-targeted therapies and disease prevention.